Cubit Diagnostics Raises Funding for New Molecular Assays

The funding will support the company’s next stage of development, including finalizing the design of its molecular CT/NG/TV assay and expanding its immunoassay testing portfolio.

The company expects to finalize the design of its CT/NG/TV molecular assay by Q4 2026, with a clinical study planned for the first half of 2027. It has also made significant progress in expanding its immunoassay program and continues to achieve key development milestones.

The funding comes after the company strengthened its board of directors by adding experienced leaders in diagnostics, regulatory affairs, and commercial operations.

"We have the right team, a clear path forward, and the capital to achieve the next key milestones," said Kunal Sur, CEO of Cubit Diagnostics. "Getting to design freeze on CT/NG/TV this year and into a clinical study in 2027 is what this phase is about. We're also making real progress on the immunoassay side, which will give us the runway to expand the menu quickly."

Read More:Solar Landscape Closes $600M Debt Facility Led by First Citizens Bank

"Putting molecular and immunoassay into one platform is novel and compelling, and we're incredibly excited about the progress we continue to make," added Kunal Sur. "Locking the CT/NG/TV design and getting into a clinical study next year is a key priority."

About Cubit Diagnostics

Founded by Kunal Sur, Cubit Diagnostics is a diagnostics company based in Carlsbad, California. The company is developing an integrated immunoassay and molecular benchtop analyzer to simplify clinical testing and improve access to quality diagnostics at the point of care. Its platform is still under development and is not yet approved for diagnostic use.

Read More:Another Nine Raises $2M in Funding